Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. The advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Elekta’s portfolio includes a range of treatment delivery systems and solutions in the fields of radiotherapy, stereotactic radiosurgery, oncology informatics, brachytherapy, neurosurgery and particle therapy. As pioneers of future technology, Elekta is setting a new standard of cancer care once again with magnetic resonance radiation therapy (MR/RT). MR/RT addresses an unmet need in cancer therapy, enabling clinicians to confidently see and track difficult to visualize soft-tissue anatomies.
The treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows.
Elekta employs 3,600 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange.